ArticleJournal of diabetes science and technology2007
Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment.
Article in Journal of diabetes science and technology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Differences in self-monitored, blood glucose test strip utilization by therapy for type 2 diabetes mellitus.Acta diabetologica · 2016Article
- Cost of clinical events in health economic evaluations in Germany: a systematic review.Cost effectiveness and resource allocation : C/E · 2012Article
- Why patients should be more empowered: a European perspective on lessons learned in the management of diabetes.Journal of diabetes science and technology · 2010Article
- [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical role and the potential benefit of self-measurement of blood glucose (SMBG) for patients with type 2 diabetes are still under discussion. Even less information is available on the cost-effectiveness of performing SMBG by this patient group. The goal of this study was to establish cost-effectiveness ratios of performing SMBG by patients afflicted by this disease.
methodsWe assessed the benefit and cost-effectiveness of SMBG in type 2 diabetes from a third-party payer perspective based on results of both a large epidemiologic cohort study reflecting the reality of care, and a Markov model calculation.
resultsAnalysis of cohort study data revealed that total costs cumulated over the observation period of 8 years were lower in the SMBG group than in the non-SMBG group according to savings of euro 1'714 [oral antidiabetic drugs (OAD) only] and euro 13'815 (OAD + insulin) per patient. Several scenarios were considered in the model-based calculation. The cost-effectiveness ratio varied from euro 20'768/life year gained to domination of SMBG use compared to nonusers in OAD treated patients and from euro 59'057/life year gained to domination of SMBG use compared to nonusers in OAD + insulin treated patients.
conclusionResults indicate that SMBG in type 2 diabetes offers an excellent opportunity to get a high investment-outcome ratio in the treatment of this pandemic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.